A Prospective Study Assessing the Predictive Value of TMPRSS2-ERG Gene Fusion and PTEN Deletion in High Risk Prostate Cancer Patients
Observational Model: Cohort, Time Perspective: Prospective
number of patients with biochemical failure showing the TMPRSS2-ERG gene fusion and/or PTEN deletion
biopsy samples of patients treated for high risk prostate cancer with radical radiation and hormonal therapy who have either biochemical failure or 3-year post treatment follow-up free of cancer recurrences will be tested for the TMPRSS2-ERG gene fusion and the PTEN deletion. The results between the two groups will be compared to see if either DNA changes are an indicator of disease recurrence.
recruitment over 2 years
Canada: Health Canada